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Interstitial lung disease in the
intensive unit care setting
Interstitial lung diseases (ILD) are a heterogeneous group
of disorders.1 Although the disease remains stable in some
patients, episodes of acute respiratory failure (ARF) requir-
ing invasive mechanical ventilation (IMV) are observed.2
Acute respiratory failure is often the result of disease pro-
gression or an acute exacerbation, but occasionally occurs
as an inaugural manifestation or as an adverse reaction to
treatment.1,3
We conducted a retrospective cohort study including
patients admitted into ICU, with previously known ILD diag-
nosis and as an inaugural event, between January 2004 and
May 2015, in order to evaluate the clinical outcome, over-
all survival and prognostic factors of ILD patients in the ICU
setting.
Thirty seven patients were included, 27 (73%) were male.
Mean age of 65.1± 11.1 years (min: 27; max: 83).
Thirty (81.1%) patients were admitted with previous ILD
diagnosis. The diagnoses of the patients admitted in ICU
were: 5 (13.5%) idiopathic pulmonary ﬁbrosis (IPF); 5 (13.5%)
silicosis; 5 (13.5%) ﬁbrotic unclassiﬁable ILD; 5 (13.5%) small
vessel vasculitis (ANCA +); 4 (10.8%) chronic hypersensitiv-
ity pneumonitis; 3 (8.2%) sarcoidosis; 2 (5.5%) rheumatoid
lung (RL); 2 (5.5%) acute interstitial pneumonitis; 2 (5.5%)
unclear ILD; 2 (5.5%) cryptogenic organizing pneumonia
(COP); 1 (2.7%) scleroderma lung and 1 (2.7%) dermato-
myositis.
Seventeen had received previous therapy with cortico-
steroids, 8 immunosuppressant therapy and 10 long term
oxygen therapy.
The median length of ICU and hospital stay were 10 days
(min: 1; max: 64) and 21 days (min:1; max:100) respectively.
Mean APACHE II score was 18.3± 7 and mean SAPS II was
36.9± 11.5.
Four lung biopsies were performed: 1 surgical lung biopsy
and 3 core needle biopsies guided by CT scan. Two of the
biopsies were consistent with acute interstitial pneumonitis,
1 with COP and 1 was unclear.
Seventeen (45.9%) patients had acute exacerbation and
twenty experienced ARF due to rapid deterioration of dis-
ease associated with respiratory infection.
Table 1 ICU and short term outcomes.
ICU P value 1 month P value
Nonsurvivors
n = 23
Survivors
n = 14
Nonsurvivors
n = 7
Survivors
n = 7
Radiology
Honeycombing 15/65.2% 4/28.6% 0.032 1/14.3% 6/85.7% 0.237
Traction bronchiectasis 15/65.2% 4/28.6% 0.032 1/14.3% 6/85.7% 0.237
Scores
APACHE II 19.3± 12.3 16.5± 5 0.198 14.3± 3.2 18.9± 7.3 0.352
SAPS 36.1± 12.3 38.4± 10.2 0.713 39± 6.9 36.6± 12.1 0.476
Thirty three patients (89.2%) required IMV, with an
median duration of 10 days (min: 1; max: 62). Nine (24.3%)
underwent non-invasive ventilation prior to IMV, 6 required
tracheostomy and 3 extracorporeal membrane oxygenation.
Thirty two patients (86.5%) were treated with antibiotics,
21 (56.8%) with corticosteroids, 8 (21.6%) with antifungals,
6 (16.2%) with cyclophosphamid, 6 (16.2%) with antivirals, 2
(5.4%) with plasmapheresis and 1 (2.7%) with rituximab.
Fourteen (37.8%) patients were discharged from the ICU:
4 small vessel vasculitis (ANCA+); 3 silicosis; 2 sarcoidosis;
2 COP; 1 ﬁbrotic unclassiﬁable ILD; 1 RL and 1 scleroderma
lung.
Twenty three 23 patients (62.2%) died in ICU: IPF (5);
chronic hypersensitivity pneumonitis (4); ﬁbrotic unclassi-
ﬁable ILD (4); silicosis (2); acute interstitial pneumonitis
(2); unclear ILD (2); sarcoidosis (1); small vessel vasculitis
(ANCA +) (1); RL (1); dermatomyositis (1). Short term mor-
tality (ﬁrst month) and overall hospital mortality were 50%
(7 patients) and 86.5% (32 patients) respectively.
Four patients did not require IMV: 1 had COP, 1 unclassi-
ﬁable ILD, 1 small vessel vasculitis (ANCA+) and 1 RL. From
this set of patients only the one with small vessel vasculitis
(ANCA+) remains alive, the others died in hospital after ICU
discharge.
A ﬁbrotic ILD with traction bronchiectasis and honey-
combing was associated with a worse outcome (p = 0.031
and p = 0.031), as well as the need of IMV (p = 0.007). A
worse outcome was not associated with a higher APACHE II
score (p = 0.198), a higher SAPS II score (p = 0.713), previous
oxygen therapy (p = 0.353) or previous immunosuppressant
therapy (0.982). None of the other parameters analyzed
were associated with a worse outcome probably due to the
small sample size (Table 1).
We found a high ICU and short term mortality rate, 62.2%
and 50% respectively. These ﬁndings are consistent with the
available literature, which indicates that progression and
exacerbation of chronic ILD generally denotes a poor out-
come once IMV has been instituted.4,5
Fibrotic ILD with CT scan evidence of ﬁbrosis, deﬁned as
traction bronchiectasis and honeycombing was associated
with a poor outcome. Traction bronchiectasis and honey-
combing indicate advanced histopathological alterations,
associated with increased lung stiffness, poorer alveolar-
capillary gas exchange and greater vulnerability of the lung
if IMV is used.3NIV 5/21.7% 4/28.6%
IMV 23/100% 10/28.6%0.639 2/28.6% 5/71.4% 1
0.007 5/71.4% 2/28.6% 1
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There was a low rate of lung biopsy, probably reﬂecting
oncern about the risk of increased morbidity and mortality
ssociated with this procedure.
The institution of IMV in these patients may raise philo-
ophical questions and would be a procedure to debate, with
ndividualized indications, mostly in cases where the disease
s not very advanced or in lung transplant candidates. Physi-
ians should discuss with patients and their relatives the
evel and degree of life support in case of clinical worsening
nd ICU admission with IMV should be needed.
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ntegrated domiciliary
entilation outpatient clinic --
escription and experience of
n integrated and
ultidisciplinary model
ong-term domiciliary ventilation has been a growing ther-
peutic option in children, namely in children with special
nd complex health care needs. For this reason, multidis-
iplinar outpatient clinics became necessary. Authors’ goal
as to describe the organizational model of an integrated
omiciliary ventilation paediatric outpatient clinic (IDVC),
escribing its ﬁrst 6 years of experience with a retrospective
ethodology.
Integrated Domiciliary Ventilation Outpatient Clinic was
reated in 2009 at Centro Hospitalar do Porto’s Paediatric
epartment in Portugal. A paediatric pulmonologist (IDVC
oordinator), a nurse and a physiotherapist with specialize
ducation in paediatric pulmonology have been the core
DVC working group. Starting in the hospital evaluation,
eneral patient assessment is done (in coordination with
arious medical specialities, optimizing hospital visits),
espiratory monitoring support equipment is adjusted and
aregivers are trained in the needed domiciliary care. Since
012 it is also possible to start long-term ventilation in the
utpatient setting, followed by a close monitoring at home.
ndividual follow-up care plan is performed in coordination
ith institutions available near home in permanent coop-
technical support and monitoring respiratory therapies,
which strengthens therapeutic adhesion and enables a rapid
and efﬁcient approach to exacerbations and ventilation
problems. The physiotherapist presence at the hospital
evaluation allows integration of technical and monitoring
data with the clinical assessment leading to a rapid and
dynamic ﬂow of information.
Between 2009 and 2014, 93 paediatric patients were
followed at IDVC and ventilation initiated in 80 patients
(9--15 new patients/year) -- Fig. 1. The majority were male
(58%) with neuromuscular disease (35.5%), malformative
syndrome (24.7%) or cerebral palsy (20.4%). Noninvasive
ventilation (NIV) was used in 95% of patients. Ventilation
had palliative goal in 90.3%, was initiated at 8.1± 6 years
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y health professionals trained in respiratory problems
nd is coordinated by IDVC physiotherapist. They perform
eriodic and urgent assessments at home, providing expert
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igure 1 New and total IDVC patients by year, since 2009 to
014.
